文献速递临床试验与 GCP基础与转化研究

ReVita:居家经皮耳迷走神经刺激减轻慢性神经及感染后病症病理性疲劳——随机双盲假对照试验方案

ReVita: home-based transcutaneous auricular vagus nerve stimulation for reducing pathological fatigue in chronic neurological and post-infectious conditions-study protocol for a randomized, double-blind, sham-controlled trial.
PubMed 文献 · Trials · 2026-08-13

本研究为在德国马格德堡大学医院开展的随机、双盲、假对照、平行组临床试验,纳入≥18岁、来自神经系统疾病和感染后综合征两个诊断集群、伴临床显著慢性疲劳的成人患者,按1:1随机接受活性taVNS或假刺激4周,每日居家自行刺激两次、每次30分钟。主要结局为MFIS评估的疲劳严重程度从基线至干预结束的变化,次要结局涵盖生活质量、抑郁症状、日间嗜睡、认知表现、神经生理标志物及HRV指标,按意向性治疗框架分析。

要点

  • 首个跨诊断评估居家taVNS治疗病理性疲劳的随机双盲假对照试验。
  • 受试者来自神经系统疾病与感染后综合征两个诊断集群,每日居家刺激两次、每次30分钟,持续4周。
  • 主要结局为MFIS疲劳严重程度变化,并同步评估临床与生理机制指标。

核心结论

  • 该试验旨在验证居家taVNS能否减轻跨诊断慢性病患者的病理性疲劳严重程度。
  • 若成功,taVNS可能为大量服务不足的患者人群提供可扩展、可及的干预手段。

研究设计与样本

  • 随机、双盲、假对照、平行组临床试验,在德国马格德堡大学医院开展。
  • 纳入≥18岁、来自神经系统疾病和感染后综合征两个诊断集群、伴临床显著慢性疲劳的成人患者,按1:1随机分组。
  • 干预为活性taVNS或假刺激4周,居家自行刺激每日两次、每次30分钟。
  • 按意向性治疗框架分析,不设中期分析,持续监测不良事件,研究结束时评估盲法完整性。

关键数值与推荐

  • 主要结局为MFIS评估的疲劳严重程度从基线至干预结束的变化。
  • 次要结局包括WHOQOL-BREF生活质量、BDI-II抑郁症状、ESS日间嗜睡、SDMT与TAP警觉性亚测验认知表现、静息态EEG与P50感觉门控神经生理标志物及Garmin Vivosmart 5的HRV指标。

临床怎么用

  • 为临床医生提供居家taVNS用于慢性神经及感染后病症病理性疲劳的循证依据前,尚需等待本试验结果。

局限性

  • 本文为试验方案,尚无疗效与安全性结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathological fatigue is one of the most prevalent and disabling symptoms across chronic neurological, post-infectious, and inflammatory diseases, yet effective treatments remain limited. Transcutaneous auricular vagus nerve stimulation (taVNS) is a safe, non-invasive neuromodulatory intervention that targets neuroimmune and autonomic pathways implicated in the development and persistence of fatigue. This randomized controlled trial investigates whether home-based taVNS can reduce fatigue severity in a transdiagnostic population. METHODS: This study is a randomized, double-blind, sham-controlled, parallel-group clinical trial conducted at the University Hospital Magdeburg. Eligible adult participants (≥ 18 years) with clinically significant chronic fatigue from two diagnostic clusters (neurological disorders and post-infectious syndromes) will be enrolled and randomized (1:1) to receive either active taVNS or sham stimulation for 4 weeks. Stimulation is self-administered at home twice daily for 30 min. The primary outcome is change in fatigue severity from baseline to the end of the intervention, assessed using the Modified Fatigue Impact Scale (MFIS). Secondary outcomes include quality of life (WHOQOL-BREF), depressive symptoms (BDI-II), daytime sleepiness (ESS), cognitive performance (SDMT and TAP subtest alertness), neurophysiological markers (resting-state EEG and P50 sensory gating) and HRV indices (Garmin Vivosmart 5). Blinding integrity will be assessed at study end. Data will be analyzed according to an intention-to-treat framework. No interim analyses are planned. Adverse events will be monitored continuously. DISCUSSION: This is to be the first transdiagnostic study to evaluate home-based taVNS as a potential therapeutic approach for pathological fatigue across multiple chronic disease groups. The combination of rigorous blinding, digital monitoring, and parallel assessment of clinical and physiological parameters allows for an in-depth evaluation of both treatment effectiveness and mechanistic correlates. If successful, taVNS could offer a scalable and accessible intervention for a large and underserved patient population. TRIAL REGISTRATION: The trial was registered in the German Clinical Trials Register (DRKS) under the identification number DRKS00038292. Registered on December 01, 2025. URL: https://drks.de/search/de/trial/DRKS00038292 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Richter A, Kuehne M, Darna M, et al. ReVita: home-based transcutaneous auricular vagus nerve stimulation for reducing pathological fatigue in chronic neurological and post-infectious conditions-study protocol for a randomized, double-blind, sham-controlled trial. Trials. 2026. PMID: 42595996. doi:10.1186/s13063-026-09919-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。